Cargando…

Room for Improvement: A 20-Year Single Center Experience with Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes

Allogeneic stem cell transplantation (allo-SCT) remains the only curative therapeutic approach for patients with myelodysplastic syndromes (MDS). The aim of the study was to assess the efficacy/safety of allo-SCT as well as to identify factors influencing post-transplant survival. One hundred and tw...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duda, Katarzyna, Wieczorkiewicz-Kabut, Agata, Spałek, Adrianna, Koclęga, Anna, Kopińska, Anna J., Woźniczka, Krzysztof, Helbig, Grzegorz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer India 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9569268/ https://www.ncbi.nlm.nih.gov/pubmed/36258723 http://dx.doi.org/10.1007/s12288-021-01508-8

Ejemplares similares

Allogeneic transplantation for high-risk chronic lymphocytic leukemia—a summary of a 16-year experience
por: Helbig, Grzegorz, et al.
Publicado: (2019)

Allogeneic hematopoietic stem cell transplantation remains a feasible approach for elderly with acute myeloid leukemia: a 10-year experience
por: Duda, Katarzyna, et al.
Publicado: (2023)

Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation
por: Helbig, Grzegorz, et al.
Publicado: (2020)

Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center
por: Kopińska, A., et al.
Publicado: (2021)

Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis
por: Helbig, Grzegorz, et al.
Publicado: (2019)

Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
por: Spałek, Adrianna, et al.
Publicado: (2022)

Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
por: Helbig, Grzegorz, et al.
Publicado: (2019)

Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis
por: Helbig, Grzegorz, et al.
Publicado: (2017)

P1349: EFFECT OF TRANSPLANTED CD184-POSITIVE CELLS (WITH EXPRESSION CXCR4) FOR A LONG SURVIVAL AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA – ONE CENTER PROSPECTIVE STUDY.
por: Kopinska, A., et al.
Publicado: (2022)

Bing-Neel Syndrome with Detectable MYD88 L265P Gene Mutation as a Late Relapse Following Autologous Hematopoietic Stem Cell Transplantation for Waldenström’s Macroglobulinemia
por: Kopińska, Anna J., et al.
Publicado: (2017)

Safety profile of autologous hematopoietic stem cell mobilization and transplantation in patients with systemic sclerosis
por: Helbig, Grzegorz, et al.
Publicado: (2017)

Spectacular and Prompt Response to Extracorporeal Photopheresis for Refractory Cutaneous Chronic Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
por: Spałek, Adrianna, et al.
Publicado: (2022)

Double Malignancy and Double Transplant—A Bumpy Road to Success
por: Razik, Michał, et al.
Publicado: (2023)

P1535: ASSESSMENT OF COLONIZATION AND INFECTION EPIDEMIOLOGY IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION – A PROSPECTIVE MULTI-CENTER STUDY OF POLISH ADULT LEUKEMIA GROUP (PALG).
por: Pluta, Agnieszka, et al.
Publicado: (2023)

Autologous hematopoietic stem cell transplantation for relapsed follicular lymphoma: safety profile and clinical outcome in a single-center experience
por: Helbig, Grzegorz, et al.
Publicado: (2014)

Rituximab is highly effective for pure red cell aplasia and post-transplant lymphoproliferative disorder after unrelated hematopoietic stem cell transplantation
por: Kopińska, Anna, et al.
Publicado: (2012)

Clinical relevance of mutant NPM1 and CEBPA in patients with acute myeloid leukaemia – preliminary report
por: Helbig, Grzegorz, et al.
Publicado: (2014)

Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome
por: Alessandrino, Emilio Paolo, et al.
Publicado: (2013)

Allogeneic hematopoietic cell transplantation in adult patients with myelodysplastic/myeloproliferative neoplasms
por: Lim, Sung-Nam, et al.
Publicado: (2013)

Autologous stem cell transplantation for mantle cell lymphoma – single centre experience
por: Szcześniak, Magdalena, et al.
Publicado: (2013)

The Influence of Genetic Variations in the CD86 Gene on the Outcome after Allogeneic Hematopoietic Stem Cell Transplantation
por: Karabon, Lidia, et al.
Publicado: (2018)

Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome and Concurrent Lymphoid Malignancy
por: Zimmerman, Zachary, et al.
Publicado: (2011)

Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic/Myeloproliferative Disorders
por: Symeonidis, Argiris, et al.
Publicado: (2022)

Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation
por: Gagelmann, Nico, et al.
Publicado: (2019)

Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy
por: Blau, Olga, et al.
Publicado: (2014)

Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome
por: Dillon, Laura W., et al.
Publicado: (2021)

Treating oral mucositis with a supersaturated calcium phosphate rinse: comparison with control in patients undergoing allogeneic hematopoietic stem cell transplantation
por: Markiewicz, Miroslaw, et al.
Publicado: (2012)

Coexistence of Chronic Lymphocytic Leukemia and Myeloproliferative Neoplasm
por: Zielinska, Patrycja, et al.
Publicado: (2014)

Short- and long-term outcome of allogeneic stem cell transplantation in infants: A single-center experience over 20 years
por: Miśkiewicz-Bujna, Justyna, et al.
Publicado: (2022)

Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes
por: Falconi, Giulia, et al.
Publicado: (2018)

P1268: ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FOR HIGH-RISK MYELODYSPLASTIC NEOPLASMS: A RETROSPECTIVE, SINGLE-CENTER ANALYSIS
por: Christian Schröder, Jan, et al.
Publicado: (2023)

Successful treatment of myelodysplastic syndrome and Behcet colitis after allogeneic hematopoietic stem cell transplantation
por: Kook, Min-Ha, et al.
Publicado: (2014)

Treatment and clinical outcomes of patients relapsing after allogeneic hematopoietic cell transplantation for myelodysplastic syndrome
por: Choi, Eun-Ji, et al.
Publicado: (2018)

Prognostic factors affecting the outcome after allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome
por: Belohlavkova, P, et al.
Publicado: (2021)

Impact of Epigenomic Hypermethylation at TP53 on Allogeneic Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndromes
por: Wang, Wei, et al.
Publicado: (2021)

Allogeneic stem cell transplantation may overcome the adverse impact of myelofibrosis on the prognosis of myelodysplastic syndrome
por: Zeng, Xiangzong, et al.
Publicado: (2021)

Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia
por: Baranwal, Anmol, et al.
Publicado: (2022)

Donor Cell-Derived Myelodysplastic Syndrome Following Allogenic Peripheral Blood Stem Cell Transplant
por: Narang, Ujjwala, et al.
Publicado: (2023)

The Efficacy of Cladribine (2-CdA) in Advanced Systemic Mastocytosis
por: Helbig, Grzegorz, et al.
Publicado: (2020)

The Elephant in The Room: AML Relapse Post Allogeneic Hematopoietic Cell Transplantation
por: Abou Dalle, Iman, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jtf6g5h649rmm8bbhgl7fhfet0